XML 72 R50.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaborative Arrangements - Schedule of Collaborative Arrangement Transactions (Details) - Collaborative Arrangement - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
AstraZeneca | Other current assets      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables from counterparty $ 128 $ 52  
AstraZeneca | Accrued and other current liabilities      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables to counterparty 577 405  
AstraZeneca | Other Noncurrent Liabilities      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables to counterparty 0 250  
AstraZeneca | Total sales      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Total sales 444 187 $ 20
AstraZeneca | Cost of sales      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Expenses 148 93 4
AstraZeneca | Selling, general and administrative      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Expenses 138 48 1
AstraZeneca | Research and development      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Expenses 168 152 2,419
Eisai | Other current assets      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables from counterparty 150 71  
Eisai | Accrued and other current liabilities      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables to counterparty 700 375  
Eisai | Other Noncurrent Liabilities      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables to counterparty 525 543  
Eisai | Total sales      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Total sales 404 149  
Eisai | Cost of sales      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Expenses 206 39  
Eisai | Selling, general and administrative      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Expenses 80 13  
Eisai | Research and development      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Expenses 189 1,489  
Bayer AG | Other current assets      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables from counterparty 49 32  
Bayer AG | Other Noncurrent Liabilities      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables to counterparty 375 375  
Bayer AG | Total sales      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Net product sales recorded by Merck 215 190 149
Merck’s profit share of sales in marketing territories 204 139 151
Total sales 419 329 300
Bayer AG | Cost of sales      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Expenses 113 216 99
Bayer AG | Selling, general and administrative      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Expenses 41 35 27
Bayer AG | Research and development      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Expenses $ 126 $ 127 $ 101